Welcome Guest
Home » Insights

White Papers [ View all ]

  • VC Funding: The Key Enabler For Biotech Start-ups?
    Published : Apr 2015

    The biotechnology and pharmaceutical industry has evolved significantly over the last several years. The growth has been led not just by established firms but also by start-ups which have shown the courage to invest a significant amount of their time and money on innovative research programs. One of the key enablers behind the emergence of start-ups is the financial support they have received from Venture Capital firms, strategic investors and... Read more

  • Pharma Landscape: Mapping the Research Focus
    Published : Aug 2014

    The pharmaceutical industry has witnessed many developments over the last decade. International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) has predicted that the pharmaceutical industry will reach approximately USD 1,200 billion by 2016. Some recent emerging phenomena have been the rise of Antibody Drug Conjugates (ADCs), development of bolus injectors, ongoing rise of sustained release medical devices and the gradual em... Read more

  • Oral Biologics: A Boon to Inflammatory Bowel Disease
    Published : Feb 2014

    Centers for Disease Control and Prevention estimates that approximately 1.4 million people in the US are suffering from Inflammatory Bowel Disease (IBD). It significantly affects the gastrointestinal tract; under the IBD umbrella, the two most common indications are Ulcerative Colitis (UC) and Crohn’s Disease (CD).   Abnormal immune response is the root cause of both illnesses; the immune system misidentifies food, bacte... Read more

  • The Hype and Hope of Anti-β-Alzheimer Therapies
    Published : Jun 2013

    In August 2012, Bapineuzumab was added to the list of Alzheimer’s drugs which have failed in clinical development. A monoclonal antibody to β-amyloid, the drug was in phase III clinical trials for the treatment of patients with mild-to-moderate Alzheimer’s. The same month saw disappointing results from phase III clinical trial of another drug, Solanezumab.   Alzheimer’s disease is a slow progressive, neu... Read more

  • ADCs: Prepare for a Meteoric Growth
    Published : Jul 2013

    Antibody Drug Conjugates are a new class of biologic therapeutics. The market is still in infancy and, currently, there are only two marketed ADC drugs. However, the pipeline is rich and the market is expected to pick up pace with the launch of several pipeline drugs in a few years   Roots Analysis has conducted an extensive study in this upcoming area; one of the key objectives of this study was to understand the future state of the ... Read more

Copyright © Roots Analysis. All Rights Reserved.
website security